NRC Health
NRCHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeNRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The $476.2M market capitalization puts NRC squarely in small-cap range for its industry. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.
Market Cap
$476.2M
Beta
0.38
P/E (TTM)
89.71
P/E (Fwd)
20.50
EPS (TTM)
$0.24
EPS (Fwd)
$1.05
ROE
42.0%
ROA
8.1%
Cash
$3.3M
Total Debt
$90.4M
Free CF
$20.3M
52W Change
36.7%
Annual Financials
Cash vs Debt
Where NRC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NRC finished 8.93% above its 150-day moving average ($18.37) and 9.28% above its 200-day moving average ($18.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NRC overbought or oversold?
At the September 3, 2026 close, NRC's RSI(14) was 33.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, NRC has $3.3M in cash with $90.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $20.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 42.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $151.6M (2022) to $137.4M (2025).
The relatively low beta of 0.38 suggests NRC is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NRC Health's trajectory.